Table 1.
Demographics and baseline characteristics in the pooled ITT-E population from GEMINI-1 and GEMINI-2.
| Demographic or characteristic | DTG + 3TC (N = 716) | DTG + TDF/FTC (N = 717) |
| Age, median (range), years | 32 (18–72) | 33 (18–70) |
| Sex, n (%) | ||
| Female | 113 (16) | 98 (14) |
| Male | 603 (84) | 619 (86) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 215 (30) | 232 (32) |
| Not Hispanic or Latino | 501 (70) | 485 (68) |
| Race, n (%) | ||
| White | 484 (68) | 499 (70) |
| African American/African heritage | 90 (13) | 71 (10) |
| Asian | 71 (10) | 72 (10) |
| Other | 71 (10) | 75 (10) |
| HIV-1 RNA, mean (SD), (log10 copies/ml) | 4.4 (0.7) | 4.4 (0.6) |
| ≤100 000 copies/ml, n (%) | 576 (80) | 564 (79) |
| >100 000 copies/ml, n (%)a | 140 (20) | 153 (21) |
| CD4+ cell count, mean (SD), (cells/μl) | 462.0 (219.2) | 461.3 (213.1) |
| ≤200, n (%) | 63 (9) | 55 (8) |
| >200, n (%) | 653 (91) | 662 (92) |
3TC, lamivudine; DTG, dolutegravir; FTC, emtricitabine; ITT-E, intention-to-treat–exposed; TDF, tenofovir disoproxil fumarate.
a
Includes 28 participants with HIV-1 RNA ≥500 000 copies/ml: 13 in the DTG + 3TC group and 15 in the DTG + TDF/FTC group.